Skip to content
Business Company News, Medical Health Aged Care

Professor Peter van Wijngaarden to become next Director and CEO of The Florey

The Florey 2 mins read
Incoming Florey Direct Professor Peter van Wijngaarden. Photo credit: Anna Carlile

The Florey Board appoints new Director and CEO  

After an extensive global search, Professor Peter van Wijngaarden has been named as the next Director and CEO of The Florey Institute of Neuroscience and Mental Health. 

Board Chair Mr Martin Adams said Professor van Wijngaarden is an outstanding leader and an experienced clinician researcher who will take The Florey’s work to the world stage. 

“On behalf of the Board, I warmly welcome Peter to The Florey. As the largest brain research centre in the Southern Hemisphere, The Florey is home to remarkably talented people committed to advancing neuroscience and mental health research. Peter is exceptionally well-placed to take The Florey’s impact to the next level.” 

Professor van Wijngaarden said he was looking forward to taking up his new role next month. 

“I am honoured to be joining The Florey as its new Director and excited to be working with scientists who are leading the world in making fundamental discoveries in neuroscience and improving diagnostics and treatments for an impressive range of mental health and brain-related conditions,” Professor van Wijngaarden said.  

“The Florey has an incredible reputation and I look forward to building on that impressive legacy,” he said. 

Mr Adams thanked retiring Director Professor Trevor Kilpatrick for his leadership and commitment to the organisation.  

"Trevor has done an outstanding job leading The Florey through a period of important structural changes which have positioned us to continue to make significant scientific breakthroughs with our partners. I’m confident that Peter will build upon these efforts.”  

Professor Kilpatrick said he was proud to have served The Florey as its sixth Director. 

“I’m delighted that Professor van Wijngaarden has accepted this appointment,” Professor Kilpatrick said.  

“I have known Peter since his return from Cambridge where he undertook research in regenerative neuroscience with my long-term friend and colleague Professor Robin Franklin. 

“Since then, Peter has had a stellar career as a clinician scientist, administrator and entrepreneur. He is ideally placed to lead The Florey in the next phase of its journey as a world-leading neuroscience and mental health-oriented research institute.” 

Peter is Professor of Ophthalmology at the University of Melbourne and has served as Deputy Director at the Centre for Eye Research Australia (CERA). 

His research interests include retinal imaging, artificial intelligence, multiple sclerosis and Alzheimer’s disease. 

 


Key Facts:
  • Professor Peter van Wijngaarden has been selected to lead The Florey from 1 August 2024 

  • Professor van Wijngaarden is currently Deputy Director of the Centre for Eye Research Australia 


About us:

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere.

Find out more about us on our website: www.florey.edu.au


Contact details:

Kathryn Powley, Media and Communications Manager

kathryn.powley@florey.edu.au | 0456 666 271

Media

More from this category

  • Government Federal, Medical Health Aged Care
  • 04/07/2024
  • 08:23
House of Representatives

Diabetes in Australia in 2024

Having completed a year-long inquiry that generated almost 500 written submissions, the House Standing Committee on Health, Aged Care and Sport today tabled an important report on the state of diabetes mellitus in Australia. Committee ChairDr Mike Freelander MPsaid: ‘In Australia, approximately 1.5 million people – some five per cent of the population – are known to live with a form of diabetes. In addition, it is expected that the number of Australians diagnosed with the condition will continue to rise. The nation faces what has throughout the inquiry been referred to as a diabetes epidemic.’ According to Dr Freelander,…

  • Government Federal, Medical Health Aged Care
  • 03/07/2024
  • 18:56
Public Health Association of Australia

Govt urged to stare down big business’ threats and enact a sugar levy?

Govt urged to stare down big business’ threats and enact a sugar levy  Media release 3 July 2024 The public health community has applauded a new parliamentary report into the causes of and solutions for diabetes andobesity, and encourages the Australian Government to stand firm against the push from big business to again dilute action on harmful, sugary products.   "The State of Diabetes Mellitus in Australia in 2024 report outlines a suite of measures to address many of the causes of diabetes and obesity in Australia, which if acted on will greatly advance the health and wellbeing of people living…

  • Contains:
  • Medical Health Aged Care
  • 03/07/2024
  • 17:11
Delta-Fly Pharma, Inc.

Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323

TOKUSHIMA, Japan–BUSINESS WIRE– We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.